Drugs / ABSK121-NX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05627063 | Jun 2023 → Mar 2026 overdue | cancer | Abbisko Therapeutics Co, Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK121-NX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05627063 ↗ |
| Route | Oral | “patients will receive a single dose of oral ABSK121-NX” NCT05627063 ↗ |